RMD

ResMed Inc

RMD, USA

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

https://www.resmed.co.in

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.6

Next Payout:

Dec 18, 2025

Yield:

0.9514 %
RMD
stock
RMD

ResMed Inc. $RMD Shares Purchased by State Street Corp MarketBeat

Read more →
RMD
stock
RMD

Cerity Partners LLC Acquires 29,205 Shares of ResMed Inc. $RMD MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$293.4667

Analyst Picks

Strong Buy

8

Buy

4

Hold

6

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

25.44

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

6.06

Low 1

High 3

Return on Equity (ROE)

-

Very Low

5.69 %

Low 5%

High 25%

Return on Assets (ROA)

-

Low

4.20 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

31.02 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.36

Low 1

High 0.3

Investors

* Institutions hold a combined 62.46% of the total shares of ResMed Inc

1.

Vanguard Group Inc

(12.804%)

since

2025/06/30

2.

BlackRock Inc

(8.4966%)

since

2025/06/30

3.

State Street Corp

(4.5186%)

since

2025/06/30

4.

Bank of New York Mellon Corp

(3.4461%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.1464%)

since

2025/07/31

6.

Geode Capital Management, LLC

(2.8789%)

since

2025/06/30

7.

Vanguard 500 Index Investor

(2.4789%)

since

2025/07/31

8.

Vanguard Mid Cap Index Institutional

(2.234%)

since

2025/07/31

9.

Morgan Stanley - Brokerage Accounts

(1.8169%)

since

2025/06/30

10.

Amvescap Plc.

(1.4915%)

since

2025/06/30

11.

Fidelity 500 Index

(1.2694%)

since

2025/07/31

12.

SPDR® S&P 500® ETF

(1.2123%)

since

2025/08/31

13.

iShares Core S&P 500 ETF

(1.2054%)

since

2025/08/31

14.

Northern Trust Corp

(1.1715%)

since

2025/06/30

15.

Vanguard Growth Index Investor

(1.1545%)

since

2025/07/31

16.

Vanguard Mid-Cap Growth ETF

(0.8364%)

since

2025/07/31

17.

NORGES BANK

(0.8113%)

since

2025/06/30

18.

UBS Asset Mgmt Americas Inc

(0.7104%)

since

2025/06/30

19.

Charles Schwab Investment Management Inc

(0.6973%)

since

2025/06/30

20.

The Health Care Select Sector SPDR® ETF

(0.6839%)

since

2025/08/31

21.

Legal & General Group PLC

(0.6635%)

since

2025/06/30

22.

Vanguard Institutional Index I

(0.6051%)

since

2025/07/31

23.

Bank of America Corp

(0.5758%)

since

2025/06/30

24.

Goldman Sachs Group Inc

(0.5695%)

since

2025/06/30

25.

Dimensional Fund Advisors, Inc.

(0.5441%)

since

2025/06/30

26.

Vanguard Dividend Appreciation ETF

(0.5378%)

since

2025/07/31

27.

State St S&P 500® Indx SL Cl III

(0.5345%)

since

2025/08/31

28.

Nordea Investment Mgmt Bank Demark A/s

(0.522%)

since

2025/06/30

29.

Barclays PLC

(0.5047%)

since

2025/06/30

30.

iShares US Medical Devices ETF

(0.4972%)

since

2025/08/31

31.

Los Angeles Capital Management LLC

(0.4596%)

since

2025/06/30

32.

Invesco OFI International Growth

(0.4113%)

since

2025/06/30

33.

Invesco S&P 500® Equal Weight ETF

(0.3844%)

since

2025/08/29

34.

Vanguard Institutional 500 Index Trust

(0.3824%)

since

2025/07/31

35.

Invesco International Growth A

(0.3796%)

since

2025/07/31

36.

Blackrock Eq Idx Fund CF

(0.3775%)

since

2025/06/30

37.

Squarepoint Ops LLC

(0.3732%)

since

2025/06/30

38.

UBS Group AG

(0.3646%)

since

2025/06/30

39.

iShares Russell Mid-Cap ETF

(0.3549%)

since

2025/08/31

40.

Fidelity Mid Cap Index

(0.3536%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

2.7

Latest Release

Date

2025-09-30

EPS Actual

2.55

EPS Estimate

2.51

EPS Difference

0.04

Surprise Percent

1.5936%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(10)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.